EF
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| Thoracic radiotherapy plus maintenance durvalumab after first line carboplatin and etoposide plus durvalumab in extensive-stage disease small cell lung cancer (ES-SCLC) - A multicenter single arm open label phase II trial (SAKK 15/19) | European journal of cancer |  | 2026 | 4 | 38 | ||
| Overall survival of recurrent/metastatic head & neck squamous cell carcinoma patients progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy : results of SAKK 11/16, a phase IIa trial | Experimental hematology & oncology | | 2025 | 60 | 58 | ||
| A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors | Cancer research communications | | 2024 | 110 | 175 | ||
| LBA46 SAKK 11/16, a phase IIa trial evaluating overall survival (OS) for recurrent/metastatic Head & neck squamous cell carcinoma (RMHNSCC) patients (pts) progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy | ESMO Congress 2023 | | 2023 | 126 | 148 | ||
| Unexpected impairment of INa underpins reentrant arrhythmias in a knock-in swine model of Timothy syndrome | Nature cardiovascular research | | 2023 | 94 | 29 | ||
| Unnecessary thyroid surgery rate for suspicious nodule in the absence of molecular testing | European thyroid journal | | 2023 | 216 | 472 | ||
| Personalized immunotherapy with encapsulated cell technology : Feasibility, safety and efficacy results from the first-in-human clinical trial in advanced relapsing solid tumors | ESMO Congress 2022 | | 2022 | 94 | 161 | ||
| Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study | Lung cancer | | 2022 | 229 | 220 | ||
| Long-term follow-up for childhood cancer survivors: the Geneva experience | Swiss medical weekly | | 2022 | 212 | 138 | ||
| Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm? | Cancer treatment reviews | | 2021 | 75 | 174 | ||
| Epidemiological changes of acute/recent human immunodeficiency virus type 1 infection in Barcelona, Spain (1997-2015): a prospective cohort study | Clinical Microbiology and Infection | | 2019 | 263 | 212 | ||
| Exclusive neoadjuvant chemotherapy in locally advanced resectable gastric and gastro-esophageal junction adenocarcinoma | | 2019 | 546 | 689 | |||
| Exclusive neoadjuvant chemotherapy in locally advanced resectable gastric and gastro-esophageal junction adenocarcinoma | Digestive and Liver Disease |  | 2017 | 552 | 1 | ||
| Les malades d'une unité de soins de support oncologiques | Revue médicale suisse | | 2017 | 370 | 184 | ||
| Early closure of fistula using neo-adjuvant intra-arterial chemotherapy in locally advanced anal cancer | Digestive and Liver Disease | | 2017 | 531 | 0 | ||
| Multiple palpebral syringomas occurring after initiation of BRAF inhibition therapy in a patient with metastatic melanoma | JAAD case reports | | 2016 | 505 | 157 | ||
| Chimiothérapie de maintenance : futile ou utile ? | Revue médicale suisse | | 2015 | 488 | 235 | ||
| A Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265) | 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015) | | 2015 | 4 | 24 |
